camptothecin has been researched along with Central Nervous System Neoplasms in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Badgett, T; Crimella, J; Fridley, BL; Gill, J; Gorlick, R; Llosa, N; Metts, JL; Reed, D; Sandler, E; Sansil, S; Smith, T; Thapa, R; Thompson, P; Trucco, M; Weiser, DA | 1 |
| Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K | 1 |
| Balañá, C; Gallego, O; García, JL; Iglesias, L; Pérez, P; Reynés, G | 1 |
| Jin, J; Joo, KM; Kang, W; Kim, KH; Kim, SU; Lee, JI; Nam, DH; Seol, HJ; Yang, H | 1 |
| Cole, BF; Eskey, CJ; Fadul, CE; Kingman, LS; Meyer, LP; Newton, HB; Pipas, JM; Rhodes, CH; Roberts, DW | 1 |
| Capri, M; Colacci, A; D'Ario, G; Farruggia, G; Horn, W; Mascolo, MG; Morandi, E; Perdichizzi, S; Quercioli, D; Serra, R; Severini, C; Silingardi, P; Vaccari, M | 1 |
| Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K | 1 |
| Andrés, R; Balañá, C; Benavides, M; de Las Peñas, R; Fernández-Chacón, C; Gallego, O; García-Velasco, A; Gil, MJ; Herrero, A; Martínez-García, M; Mesia, C; Pérez-Martin, X; Peréz-Segura, P; Quintanar, T; Reynés, G | 1 |
| Matsko, MV | 1 |
| Bigner, DD; Colvin, OM; Dolan, ME; Friedman, HS; Houghton, PJ; Keir, S; Moschel, RC; Pegg, AE | 1 |
| Buster, WP; Gruber, ML | 1 |
| Motl, S; Stewart, CF; Waters, CM; Zhuang, Y | 1 |
| Bigner, DD; Friedman, HS; Houghton, PJ; Keir, S; Schold, SC | 1 |
| Cheson, BD; Phillips, PH; Wilson, WH | 1 |
| Boothman, DA; Lamond, JP; Mehta, MP | 1 |
| Prados, M | 1 |
| Cloughesy, TF; Elfring, GL; Filka, E; Friedman, H; Kabbinavar, F; Miller, LL; Nelson, G | 1 |
2 review(s) available for camptothecin and Central Nervous System Neoplasms
| Article | Year |
|---|---|
Pharmacokinetic considerations in the treatment of CNS tumours.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Central Nervous System Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation, Preclinical; Humans; Methotrexate | 2006 |
Temozolomide in combination with other cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carmustine; Central Nervous System Neoplasms; Clinical Trials as Topic; Dacarbazine; Drug Implants; Glioma; Humans; Irinotecan; Temozolomide | 2001 |
6 trial(s) available for camptothecin and Central Nervous System Neoplasms
| Article | Year |
|---|---|
A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Dacarbazine; Humans; Irinotecan; Maximum Tolerated Dose; Metformin; Neoplasm Recurrence, Local; Neoplasms; Sarcoma, Ewing; Temozolomide; Vincristine | 2023 |
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult | 2013 |
A phase I study of irinotecan in combination with metronomic temozolomide in patients with recurrent glioblastoma.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioblastoma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Temozolomide | 2014 |
A phase II study of thalidomide and irinotecan for treatment of glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Disease Progression; Female; Glioblastoma; Humans; Immunosuppressive Agents; Irinotecan; Male; Middle Aged; Survival Analysis; Thalidomide | 2008 |
Temozolomide in combination with irinotecan for treatment of recurrent malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Dacarbazine; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Treatment Outcome | 2004 |
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen.
Topics: Adult; Antineoplastic Agents; Camptothecin; Central Nervous System Neoplasms; Drug Administration Schedule; Enzyme Inhibitors; Female; Glioma; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Topoisomerase I Inhibitors | 2002 |
9 other study(ies) available for camptothecin and Central Nervous System Neoplasms
| Article | Year |
|---|---|
Genetically-engineered human neural stem cells with rabbit carboxyl esterase can target CNS lymphoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Base Sequence; Bystander Effect; Camptothecin; Carboxylesterase; Central Nervous System Neoplasms; DNA Primers; Genetic Engineering; Humans; Irinotecan; Lymphoma; Male; Mice; Mice, Inbred BALB C; Neural Stem Cells; Rabbits; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cellular Senescence; Central Nervous System Neoplasms; DNA Topoisomerases, Type I; Flow Cytometry; Gene Expression; Glioblastoma; Humans; Interleukin-1beta; Oligonucleotide Array Sequence Analysis; Phenotype; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53 | 2008 |
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Compassionate Use Trials; Dacarbazine; Disease Progression; Glioma; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Temozolomide; Treatment Outcome | 2012 |
[Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Doxorubicin; Drug Administration Schedule; Glioma; Humans; Irinotecan; Temozolomide | 2012 |
O6-benzylguanine-mediated enhancement of chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Camptothecin; Carmustine; Central Nervous System Neoplasms; Cyclophosphamide; Dacarbazine; DNA; Enzyme Inhibitors; Female; Guanine; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Protein Synthesis Inhibitors; Temozolomide | 2002 |
Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts.
Topics: Adult; Animals; Antineoplastic Agents; Camptothecin; Central Nervous System Neoplasms; Child; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Random Allocation; Time Factors; Topotecan; Transplantation, Heterologous | 1994 |
Clinical trials at the medicine branch of the NCI-part 2.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Central Nervous System Neoplasms; Clinical Trials as Topic; Eye Neoplasms; Humans; Immunotherapy; Lymphoma; Lymphoma, Non-Hodgkin; Recurrence | 1995 |
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Topics: Antineoplastic Agents; Camptothecin; Cell Survival; Central Nervous System Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; Glioma; Humans; Radiation-Sensitizing Agents; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1996 |